Intensive BP control can delay kidney replacement therapy in Stage 4/5 CKD

Written By : Dr.Niharika Harsha B |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-01-23T20:00:14+05:30 | Updated On 24 Jan 2023 1:19 PM IST

Recent research found that intensive blood pressure control has a beneficial effect of delaying kidney replacement therapy in stage 4 and 5 chronic kidney disease patients. The study results were published in the Journal of the American Society of Nephrology.

Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states where sustained hypertension can worsen renal function leading to a progressive decline in kidney function thus worsening blood pressure (BP) control. It is quite necessary to have intensive blood pressure control where a systolic BP of <120 mmHg is maintained. As there is uncertainty about the effect of intensive BP lowering on the risk of kidney failure requiring kidney replacement therapy (KRT) in patients with advanced CKD, researchers conducted a pooled analysis to examine the effect of intensive BP lowering on KRT risk.

Also Read: Albuminuric diabetic kidney disease may increase risk of Diabetic Foot Ulcer by two to three folds

A pooled analysis of individual-level data from seven trials was carried out by including patients with eGFR<60 mL/min per 1.73 m2. A prespecified subgroup analysis was carried out to evaluate the effect of intensive BP control by baseline albuminuria and eGFR (CKD stage 4–5 versus stage 3).

Key findings of the study:

Among the 5823 trial participants, 526 developed the kidney outcome and 382 died.
Even though there was no statistical significance, intensive (versus usual) BP control was associated with a lower risk of kidney outcome and death in unadjusted analyses.
Based on the baseline eGFR, the intervention’s effect on the kidney outcome varied (P interaction=0.05).
By intention-to-treat analysis, intensive (versus usual) BP control was associated with a 20% lower risk of the primary kidney outcome in those with CKD GFR stage 4–5, but not in CKD GFR stage 3.
There was no interaction between intensive BP control and the severity of albuminuria for kidney outcomes.

Also Read: Patients with severe tricuspid regurgitation may have adverse events in long run

Thus, the pooled analysis suggested no evidence of harm but an advantage of intensive BP control in delaying kidney replacement therapy in patients with stages 4–5 CKD but not stage 3 CKD.

Further reading: Ku, Elaine, McCulloch, Charles E, Inker, Lesley A, et al. Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes. Journal of the American Society of Nephrology. January 17, 2023. | DOI: 10.1681/ASN.0000000000000072

journal of the american society of nephrologyMeta-analysisKidney diseaseBlood pressure

Source : Journal of the American Society of Nephrology

Dr.Niharika Harsha B

BDS, MDS

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751